ftInvstr

HESTERBIO · Healthcare ₹2330.0 -1.5% Mkt Cap ₹2006 Cr overvalued

HESTERBIO

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹2330.0

-1.5% today · 30d +12.76%

as of 2026-11-09

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for HESTERBIO. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-09-30

REVENUE

₹98 Cr

+37.96% YoY

NET PROFIT

₹21 Cr

+43.96% YoY

OPM

34.38%

+7.81pp YoY

EPS

₹23.94

PE 14.56

Intrinsic value · DCF ₹832.10 · Margin of safety -64.3% (overvalued) · FCF yield 2.31%

◇ Sector Position

PEERPEROCE %

HESTERBIO14.5615.0

SUNPHARMA37.7921.44

DIVISLAB93.121.56

ZYDUSLIFE28.424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance STRONG 90

Valuation CHEAP 75

Growth STEADY 68

Profitability HIGH 85

Technicals NEUTRAL 57

Risk MODERATE 50

Key Stats

TTM PE

14.56

P/B

4.26

52W HIGH

₹2683.6

OFF HIGH

-13.18%

DIV YIELD

0.48%

MKT CAP

₹2006 Cr

◉ Active Signals

MACDBullish19.0903

RSI(14)Neutral56.69

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold HESTERBIO and at what entry.